DiaMedica Expands DM199 into Preeclampsia with Phase 2 Trial Starting Q4 2024

DiaMedica Therapeutics Inc.

Phase 2 open-label, single-arm, investigator-sponsored trial enrolling up to 120 preeclampsia/FGR patients; first subject Q4 2024, topline results H1 2025.
Trial cost estimated at ~$1.5M; led by Prof. Catherine Cluver (Stellenbosch Univ.) with collaboration from Prof. Stephen Tong (Univ. Melbourne).
DM199 did not cross the placental barrier in rat studies; prior REDUX CKD data showed SBP reduction of 12.6 mmHg (p=0.004) in patients with baseline SBP ≥140 mmHg.
No approved therapeutics for preeclampsia in US/Europe; DM199 is a large-molecule protein (rhKLK1) that may improve placental perfusion and reduce hypoxia.
Company to host KOL event on July 29, 2024; conference call on June 27, 2024 at 8:00 AM ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.